Hillstream BioPharma Terminates Agreement with Intract Pharma Ltd, Appoints New Board MemberWASHINGTON, D.C. — On November 20, 2024, Tharimmune, Inc., with its principal executive offices located in Bridgewater, New Jersey, filed a Form 8-K with the

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hillstream BioPharma’s 8K filing here. About Hillstream BioPharma (Get Free Report) Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell […]

Leave a Reply

Your email address will not be published.

Previous post CBRE Group, Inc. Announces Increase in Stock Repurchase Authorization
Next post Europe October 2024: Skoda (+28.2%), Volvo (+22%), Volkswagen (+18.1%) impress